Anti-ECSCR ADCC Enhanced Antibody is an ADCC enhanced antibody produced by our Afuco™ platform. They are antibodies which bind ECSCR and inhibit chemotaxis. The antibodies may bind an epitope QTVPPNSTTM on the extracellular domain of ECSCR. The antibodies, which may be provided as a pharmaceutical composition, may be used to inhibit tumour cell invasion and may be used in the treatment of diseases, for example diseases associated with angiogenesis such as cancer.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-3014z | Recombinant Anti-Human ECSCR Antibody | ELISA, IP, FuncS | IgG |
There are currently no Customer reviews or questions for AFC-212CL. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.